Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Name

Click to order products ascending

Display 15 Products per page

Abraxane
Read More
Abraxane (nab-paclitaxel; Bristol-Myers Squibb) is a novel albumin-bound formulation of paclitaxel. Paclitaxel is an insoluble taxane classified as an anti-microtubule agent; it stops the growth of tumors by inhibiting mitosis during metaphase.
February 26, 2020
Find out more
Abuse-Deterrent Opioids Survey KOL Interview

$599.00

Biomedtracker performed a 5-question survey of 30 United States primary care physicians who currently treat patients with chronic pain and prescribe opioids to at least some of their patients with chronic pain to gauge current and future use of abuse-deterrent opioids to treat chronic pain.
March 9, 2017
Find out more
Access in Emerging Markets: HTA is Making Inroads

$2,995.00

Generally considered the domain of developed markets, health technology assessment (HTA) is increasingly being used by developing countries as a means of reconciling growing demand for access to health technologies with limited resources. Expanding public health insurance programs, coupled with aging populations and growing patient empowerment, have led in some cases to the fast establishment […]
November 2, 2016
Find out more
Access Trends in Emerging Markets

$3,000.00

This report provides an in-depth analysis of the market access climate in emerging pharmaceutical markets. Focusing in particular on the E7 countries (Brazil, Russia, India, China, Mexico, Indonesia, and Turkey), it charts recent developments, assesses their potential impact on market access, and pinpoints areas in which further change is anticipated.
February 20, 2019
Find out more
Accountable Care Organizations – What Impact on Pharma

$7,500.00

This strategy report focuses Accountable Care Organizations and what impact they will have on pharma including an evaluation of ACOs’ structures, sizes, cultures, and risks.
July 16, 2015
Find out more
Acne Prescribing Practices Pulse Survey

$599.00

We performed a survey of 10 dermatologists currently practicing in the US to gauge

prescribing practices for the treatment of acne.
November 29, 2016
Find out more
Actelion

$3,000.00

Analysis of Actelion’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
November 1, 2016
Find out more
Actemra
Read More
Actemra (tocilizumab; Roche/Chugai), known as RoActemra in Europe, is a first-in-class humanized interleukin-6 receptor monoclonal antibody.
March 24, 2015
Find out more
Activase
Read More
Activase (alteplase; Roche/Boehringer Ingelheim/Kyowa Hakko Kirin) is a recombinant tissue plasminogen activator, and is a manufactured version of the tissue plasminogen activating proteins found naturally in endothelial cells.
July 2, 2018
Find out more
Acute Lymphocytic Leukemia KOL Interview

$599.00

[Newer treatments] are definitely being used in the relapse population, and that’s where they made their mark like most other investigational agents for other cancers. I think the issue is that the response rate with initial induction therapy is so high. Whether or not there is going to be a maintenance-type study strategy, that’s a question with some of these therapies that are relatively low toxicity, but when you have a complete remission rate of 90-95%, and ALL’s not the most common disease – it’s a pretty rare cancer actually – that it’s going to be difficult to do large studies for indications in the randomized setting.
February 9, 2016
Find out more
Acute Myelogenous Leukemia (AML) KOL Interview

$599.00

Datamonitor interviewed three oncology specialists to determine the physicians’ views on marketed and pipeline therapies for Acute Myelogenous Leukemia. Two physicians were based in the US (Greater Midwest and Greater Boston areas) and one in the UK. The three interviews were combined into a single report.
August 19, 2016
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – Italy

$599.00

An interview with an Italian key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Onureg, Idhifa, Tibsovo, magrolimab, crenolanib, gilteritinib, and Iomab-B.
March 14, 2022
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include ASTX727, guadecitabine, idasanutlin, Iomab-B, oral azacitidine, pevonedistat, and Zeltherva.
April 1, 2020
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – UK

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.
March 14, 2022
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – US, East Coast

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.
April 1, 2020
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *